Epidiolex Phase III Trial Safety and Efficacy Data for Dravet and Lennox‑Gastaut Syndromes

Epidiolex Phase III Trial Safety and Efficacy Data for Dravet and Lennox‑Gastaut Syndromes The passage contains only publicly available clinical trial results for a pharmaceutical product, with no mention of high‑profile individuals, government agencies, or controversial financial flows. It offers no actionable investigative leads. Key insights: Phase III trial in Dravet syndrome shows modest seizure reduction with CBD vs. placebo.; Common adverse events include somnolence, diarrhea, decreased appetite, fatigue, pyrexia, and vomiting.; Elevated liver enzymes occurred primarily in patients on concomitant valproic acid.